Business Wire

AgroAmerica Contributes Once Again to the Development of the Central American Region

5.9.2020 04:26:00 EEST | Business Wire | Press release

Share

AgroAmerica, a globally recognized sustainable company, has been invited since 2017 to sponsor the Central American Donors Forum, an initiative of the Seattle International Foundation (SIF), to generate alliances and advance in development efforts in Central America to generate a greater social impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005525/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

For the 4th consecutive year, AgroAmerica participated as a sponsor of the Central America Donors Forum, promoting the development of the region. (Graphic: Business Wire)

The Forum has the participation of over 400 leaders from business, government, private sector, media outlets, and civil society, as well as international and regional panelists, to discuss priority issues and promote Social Responsibility. For the first time since its inception, the 2020 Forum was held virtually and was open to all audiences.

From September 1 - 3, 2020, the interventions of the different Forum participants focused on the “Reinvention and resistance in times of crisis”. The COVID-19 pandemic has exposed many of the vulnerabilities and concerns of Central America based on the construction of alternative responses to the economic impact, gender approach, migration, and the role of companies to increase market access for all.

Promoting development:

For the 4th consecutive year, AgroAmerica participated as a sponsor of the Forum, promoting the development of the Central American region and the implementation of good business, labor, social and environmental practices.

During 2019, the Forum's central theme was “Progress at the Crossroads”. More than 30 conferences, panels, and workshops were held in Tegucigalpa, Honduras, addressing Economic Development, Youth, Feminist Movements, Corruption, Migration, Human Rights, Democracy, Public-Private Partnerships, among others.

In 2018, the forum was held in San Salvador, El Salvador, developing the theme “Creating space for everyone”, highlighting the role of corporate social responsibility in building a more inclusive region through strategic alliances with social actors.

In 2017, AgroAmerica CEO, Fernando Bolaños, was a member of the host committee, as well as a panelist of the Forum that revolved around the theme “Reimagining Partnerships” held in Panama City.

Bolaños participated on the panel Social Responsibility: The Role of Influential People in the Construction of Democracy in Central America. “There are many challenges facing Central America,” said Bolaños during his intervention. “Our challenges are all connected and linked – food security, poverty, gender equality, health and education to name just a few. At AgroAmerica we strive to create a sustainable development initiative through partnerships, so we can improve the lives of our employees and the people in the surrounding communities.”

AgroAmerica will continue contributing to initiatives that promote a more inclusive region through its Corporate Sustainability Strategy and strategic alliances with social actors.

About AgroAmerica:

AgroAmerica is an agroindustrial corporation dedicated the production and commercialization of food products, using sustainable and responsible farming methods. With operations in Europe, United States, México, Guatemala, Ecuador, Perú, and Panamá. AgroAmerica operates based on a Corporate Sustainability strategy to generate value and balance among economic growth, natural resource conservation, and our customers and stakeholders wellbeing. Visit us: https://agroamerica.com/en/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
(502) 2420-9600

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye